Why Is the Recurrence of Early Breast Cancer in the Double Digits?
The explanation is multifaceted.
San Francisco United States New York Eleonora Teplinsky Anne Peled Icahn School Of Medicine At Mount Sinai
Source: yahoo.com
📰 Recurrence Risk News
Recurrence Risk News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Recurrence Risk. Real-time updates on events, politics, business and more.
Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries
A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.
United States South Korea Cara Schafer Prostate Disease Research Department Of Surgery Uniformed Services University Of The Health Sciences
Source: onclive.com
XtalPi and CK Life Sciences Ink Agreement to Develop Cancer Molecular Diagnostic Models using AI and Biomarker Data
Today, XtalPi, a leading global technology company in combining artificial intelligence (AI) and robotics to drive the discovery of groundbreaking medicine and innovative materials, announced the signing of a new agreement with CK Life Sciences, a member of the CK Hutchison Group. Expanding upon their existing partnership, the two companies will combine AI algorithms with anonymized clinical and biomarker data from cancer patients and healthy individuals in CK Life Sciences' data repository...
Source: yahoo.com
Second-Line Therapy for Metastatic TNBC
Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.
Shay Elkins Noor Abuhadra Metastatic Triple Negative Breast Cancer Overcoming Challenges Diagnosis Treatment Online Therapy
Source: curetoday.com
Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer
New data highlights two novel proteomic tests that support treatment decision making in patients with non-small cell lung cancer : Expanded analysis of the VeriStrat® host immune classifier’s...
Wallace Akerley Langone Health Lung Cancer Disease Center Research For Cardiothoracic Surgery Perlmutter Cancer Institute Biodesix Inc
Source: marketscreener.com
Scenario 3: A 44-Year-Old Woman With RCC at Intermediate-High Risk for Recurrence
Expert panelists highlight aspects of a final patient scenario, discussing adjuvant treatment strategies in the setting of renal cell carcinoma at intermediate-high risk for recurrence.
Optimizing Outcomes Patients With Translating Evidence Clinical Practice Year Old Woman With Intermediate High Risk
Source: onclive.com
Strong Analytical Validation Data Further Supports Use of DCISionRT® to Guide Shared Decision-Making for DCIS Therapeutic Management
/PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced that...
Source: prnewswire.com
Guardant Health Files Lawsuit Against Natera for Misleading Oncologists
Posted on 465 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today filed a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and the performance of Guardant Health’s new oncology test, Guardant Reveal™. Guardant Health asked the federal court in San Francisco, California for an in...
Source: financialbuzz.com